Departed
Jeff Schwaneke
Director
AGL ·
agilon health, inc.
In connection with his appointment, Mr. Schwaneke will resign from the agilon health, inc. Board of Directors.
Ready 8-Ks
23
Latest filing
June 3, 2026, 4:31 PM ET
Top materiality
0.85
Event mix
earnings ×9 · other ×4 · leadership ×4
Sentiment
1 pos · 10 neg · 12 neu
Latest earnings
reported 2026-Q1
Executive change
recent →
Recent 8-K filings for AGL
Highest-materiality recent filing
CEO Sell resigns; agilon posts $104M Q2 net loss, suspends 2025 guidance
- Steven Sell resigned as CEO/President and Board director effective July 29; Board reduced to seven directors.
- Executive Chairman Ron Williams appointed; Office of the Chairman formed to oversee interim operations.
-
agilon health annual meeting votes; all three proposals approved
Diana McKenzie, Karen McLoughlin, Ronald Williams elected Class II directors through 2029.
-
Q1 net income $49M vs $12M YoY; Adjusted EBITDA $54M vs $21M; medical margin $149M vs $128M.
-
agilon health appoints Tim O'Rourke as CEO, effective May 7, 2026
Tim O'Rourke appointed CEO/President, effective May 7, 2026; joins Board as Class III director.
-
agilon health completes 1-for-25 reverse stock split effective March 30, 2026
Ratio set at 1-for-25; approved by stockholders at March 17, 2026 special meeting.
-
agilon health to effect 1-for-25 reverse stock split on March 30, 2026 to maintain NYSE listing
Stockholders approved reverse split at special meeting on March 17; votes were 356,574,789 for, 6,187,388 against, 365,864 abstained.
-
agilon health Q4 net loss $189M, revenue $1.57B; 2026 guidance Adj EBITDA breakeven
Q4 net loss $189M vs $106M loss YoY; FY net loss $391M vs $260M loss.
-
agilon health amends credit agreement, extends maturity to 2028, reduces revolver to $90M
Maturity extended from Feb 2026 to Feb 2028 for $90M revolver (down from $100M).
-
agilon health amends CFO Schwaneke's employment agreement with enhanced equity and severance
One-time award of 600,000 RSUs vesting over three years.
-
agilon health receives NYSE delisting notice; plans reverse stock split
NYSE notified agilon on Nov 5, 2025 that avg closing price was below $1.00 over 30 trading days ended Nov 4, 2025.
-
agilon health Q3 net loss $110M; re-establishes FY2025 guidance with negative EBITDA outlook
Q3 2025 revenue $1.44B, down 1% YoY; net loss $110M vs $118M loss in Q3 2024.
-
CEO Sell resigns; agilon posts $104M Q2 net loss, suspends 2025 guidance
Steven Sell resigned as CEO/President and Board director effective July 29; Board reduced to seven directors.
-
agilon health shareholders approve all proposals at annual meeting
Silvana Battaglia and Sharad Mansukani elected as Class I directors; Battaglia: 367.7M for, Mansukani: 316.0M for.
-
agilon health Q1 2025 revenue $1.53B, net income $12M; reaffirms FY 2025 guidance
Total revenue $1.53B (down 4% YoY); Medicare Advantage members 491,000 (down 6%).
-
Q4 revenue $1.52B (+44% YoY); full-year revenue $6.06B (+40%). Medicare Advantage members 527,000 (+36%).
-
On Dec 4, 2024, agilon health began entering new indemnification agreements with its directors, executive officers, and certain officers, replacing prior agreements.
-
agilon health presents at Wolfe Research Healthcare Conference; details limited
Presentation on Nov 19, 2024 at 2:20 PM ET; webcast replay available on IR site.
-
Medicare Advantage members grew 37% to 525,000; total platform members 657,000 (+39% YoY).
-
agilon health Q2 revenue up 39% to $1.48B but net loss widens to $31M
Revenue $1.48B (+39% YoY); MA membership 513K (+38%).
-
agilon health appoints Jeff Schwaneke as CFO, replacing retiring Tim Bensley effective July 1, 2024
Jeff Schwaneke, former Centene CFO (2016-2021) and EVP Health Care Enterprises, named CFO and EVP effective July 1, 2024.
-
Three Class III directors elected: Ravi Sachdev, Steven J. Sell, William Wulf, M.D., each with over 359M votes for.
-
agilon health Q1 revenue up 52% to $1.6B, net loss $6M; lowers FY2024 member & revenue guidance
Revenue $1.60B (+52% YoY); net loss of $6M vs net income $16M in Q1 2023.
-
Agilon health Q4 net loss $230M, medical margin negative $102M; FY2024 guidance slashed
Q4 revenue $1.06B (+72% YoY) but gross profit of negative $95M vs $16M a year ago.
-
Benjamin Kornitzer, M.D., transitions from CMO to special advisor effective March 1, 2024.
Executive changes
Appointed
Jeff Schwaneke
Chief Financial Officer and Executive Vice President
AGL ·
agilon health, inc.
On June 4, 2024, agilon health, inc. (the “Company”) appointed Jeff Schwaneke to serve as the Company’s Chief Financial Officer and Executive Vice President effective July 1, 2024 (the “Effective Date”).
Appointed
(interim)
Karthik Rao
Interim Chief Medical Officer
AGL ·
agilon health, inc.
Until a successor is named, Dr. Karthik Rao, senior medical director and vice president, network performance, will serve as interim CMO.
Role change
Benjamin Kornitzer, M.D.
Chief Medical Officer
AGL ·
agilon health, inc.
Effective March 1, 2024, Benjamin Kornitzer, M.D., will assume a strategic role as special advisor to agilon health and will transition from his role as chief medical officer (CMO).
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.70 · Most common event earnings